CERO THERAPEUTICS HOLDINGS I (CERO) Stock News
NASDAQ:CERO - Nasdaq - US71902K1051 - Common Stock
CERO Latest News and Analysis
Top movers in Wednesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
These stocks are the most active in today's session
Curious about the stocks that are showing activity before the opening bell on Tuesday?
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy...
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy...
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics...
CERo Therapeutics, Inc. Provides Corporate Update
CERo Therapeutics, Inc. Provides Corporate Update
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo...
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy...
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN...
CERO Stock Earnings: CERo Therapeutics Hldgs Reported Results for Q2 2024
CERo Therapeutics Hldgs just reported results for the second quarter of 2024.
CERO Stock Earnings: CERo Therapeutics Hldgs Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CERo Therapeutics Hldgs (NASDAQ:CERO) just reported results for the second quar...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!